PlainRecalls
FDA Drug Critical Class I Terminated

REVITADERM WOUND CARE GEL, (Benzalkonium Chloride in a gel containing transforming growth factor-b), 0.1%, packaged in 29.6 mL (1.0 FL OZ) bottles (NDC 63347-120-02) and 88.7 mL (3.0 FL OZ) tubes (NDC 63347-120-01), Blaine Labs Inc., Santa Fe Springs, CA 90670

Reported: March 30, 2022 Initiated: January 25, 2022 #D-0668-2022

Product Description

REVITADERM WOUND CARE GEL, (Benzalkonium Chloride in a gel containing transforming growth factor-b), 0.1%, packaged in 29.6 mL (1.0 FL OZ) bottles (NDC 63347-120-02) and 88.7 mL (3.0 FL OZ) tubes (NDC 63347-120-01), Blaine Labs Inc., Santa Fe Springs, CA 90670

Reason for Recall

Microbial Contamination of Non-sterile Product; FDA analysis found the product to be contaminated with Bacillus cereus.

Details

Recalling Firm
Blaine Labs Inc
Units Affected
1119 (1 oz.) bottles/ 772 (3 oz.) tubes
Distribution
Nationwide in 17 States to 45 doctors.
Location
Santa Fe Springs, CA

Frequently Asked Questions

What product was recalled?
REVITADERM WOUND CARE GEL, (Benzalkonium Chloride in a gel containing transforming growth factor-b), 0.1%, packaged in 29.6 mL (1.0 FL OZ) bottles (NDC 63347-120-02) and 88.7 mL (3.0 FL OZ) tubes (NDC 63347-120-01), Blaine Labs Inc., Santa Fe Springs, CA 90670. Recalled by Blaine Labs Inc. Units affected: 1119 (1 oz.) bottles/ 772 (3 oz.) tubes.
Why was this product recalled?
Microbial Contamination of Non-sterile Product; FDA analysis found the product to be contaminated with Bacillus cereus.
Which agency issued this recall?
This recall was issued by the FDA Drug on March 30, 2022. Severity: Critical. Recall number: D-0668-2022.